Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment
of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. It has a research collaboration with Keck School of Medicine of University of Southern California using pelareorep in combination with Keytruda, Velcade, and dexamethasone to treat multiple myeloma; and a clinical collaboration with SOLTI breast cancer research. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada. The company trades on NASDAQ exchange. The company headquarter is located in Calgary, AB. The company was established in the 1998.
| Ticker | ONCY |
| Long Name | Oncolytics Biotech Inc. |
| Short Name | Oncolytics Biotech |